Maffezzini M, Rigatti P
Istituto Scientifico San Raffaele, Divisione di Urologia.
Arch Ital Urol Nefrol Androl. 1990 Jun;62(2):219-21.
A total of 25 patients with locally advanced bladder cancer, staged T3 and T4, have received neo-adjuvant VMC chemotherapy with Vinblastine, Methotrexate and Cisplatinum. The evaluable patients were 21 and after cystectomy demonstrated the following responses: pCR in one case (4%), pRP in ten cases (48%), pNC in 10 patients (48%). Toxicity was mainly represented by leukopenia in 18 patients (82%), one of them died from neutropenic sepsis. After a median follow-up time of 12 months (range 6-39) 5 patients already experienced relapse of the disease.
共有25例局部晚期膀胱癌（分期为T3和T4）患者接受了长春碱、甲氨蝶呤和顺铂的新辅助VMC化疗。可评估的患者有21例，膀胱切除术后显示出以下反应：1例（4%）达到病理完全缓解（pCR），10例（48%）达到病理部分缓解（pRP），10例（48%）达到病理无变化（pNC）。毒性主要表现为18例（82%）患者出现白细胞减少，其中1例死于中性粒细胞减少性败血症。中位随访时间为12个月（范围6 - 39个月）后，5例患者已出现疾病复发。
